Clinical Trials
3 trialsNCT06277154 2025-07-24
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase 2 Recruiting
NCT02150213 2016-12-05
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Novartis
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed